October 2026 Biotech Catalysts: Two PDUFAs Ranked

Update September 27, 2026: Merck and Daiichi Sankyo voluntarily withdrew the I-DXd BLA for previously treated ES-SCLC on September 25 after the FDA said the Phase 2 IDeate-Lung01 data do not support accelerated approval. The October 10 PDUFA is off, cutting this slate from three catalysts to two (see our withdrawal coverage). The I-DXd section below is retained for the record.

October 2026 had been the densest PDUFA month of the fall, but the slate just got shorter. Two FDA decisions now land in the window: bepirovirsen on October 26 and INO-3107 on October 30. Each targets a different disease at a different market cap. Together they tell you where the biotech market is pricing binary regulatory risk heading into Q4.

Here is the setup. September had its own slate, and the Q4 FDA calendar covers the full quarter. This piece ranks the two remaining October catalysts by tradeable risk-reward, with live market caps pulled from Polygon on August 1. Each links to a dedicated primer for the deep dive.

Catalyst 1 (withdrawn): I-DXd (Oct 10) - The ADC Bet That Cannot Miss

Withdrawn September 25, 2026 — Merck and Daiichi Sankyo pulled the I-DXd BLA after the FDA said the Phase 2 IDeate-Lung01 data do not support accelerated approval. See our withdrawal coverage. The analysis below is preserved from the August 2 original.

Merck (MRK) at $130.20, $321 billion market cap. Daiichi Sankyo is the development partner.

Ifinatamab deruxtecan (I-DXd) is a B7-H3-directed antibody-drug conjugate targeting extensive-stage small cell lung cancer (ES-SCLC), the most aggressive form of lung cancer with a 3% five-year survival rate. The BLA is based on the Phase 2 IDeate-Lung01 trial, where the 12 mg/kg cohort showed a 54.8% confirmed ORR (95% CI: 38.7 to 70.2), median PFS of 5.5 months, and median OS of 11.8 months. The 8 mg/kg cohort showed a 26.1% ORR, suggesting a steep dose-response. The FDA granted Priority Review and Breakthrough Therapy designation for I-DXd in SCLC. The confirmatory Phase 3 IDeate-Lung02 trial (NCT06203210) is already enrolling.

The binary question is narrow. SCLC has no approved targeted therapy for the post-platinum setting. Tarlatamab (Amgen) won accelerated approval in May 2024 for the same line, with a 40% ORR. I-DXd at 54.8% ORR is numerically superior, and the B7-H3 target is expressed in roughly 65% of SCLC tumors. The FDA has a clear precedent for approving ADCs and bispecifics in refractory SCLC on single-arm ORR data. The confirmatory Phase 3 IDeate-Lung02 trial (NCT06203210) is already enrolling. The intracranial ORR data is also notable: 50% CNS response rate in the 12 mg/kg cohort, addressing the brain metastasis burden that defines SCLC outcomes.

But at $321 billion market cap, this approval moves the stock zero. I-DXd peak sales in ES-SCLC are estimated at $1 to $2 billion, which is 0.3% to 0.6% of Merck’s revenue base. The ADCs explained guide covers why the DXd payload platform is the franchise’s real value driver. The tradeable play here is not MRK. It is the entire B7-H3 ADC space, where I-DXd approval validates the target and de-risks the pipeline.

Catalyst 2: Bepirovirsen (Oct 26) - The Functional Cure That Redefined HBV

GSK (GSK) at $51.69, $104 billion market cap. Ionis (IONS) at $51.77, $8.85 billion market cap. GSK holds commercial rights; Ionis receives royalties and milestone payments.

Bepirovirsen is an antisense oligonucleotide targeting hepatitis B virus transcripts, dosed as a weekly subcutaneous injection for 24 weeks. The B-Well 1 and B-Well 2 Phase 3 trials (NCT05630807, NCT05630820) enrolled 1,838 patients with noncirrhotic chronic HBV on stable nucleos(t)ide analogue therapy. The primary endpoint was functional cure at week 72, defined as HBV DNA below the lower limit of quantification plus HBsAg loss for at least 24 weeks after stopping all therapy.

The results, published in NEJM on May 28, 2026, were striking. B-Well 1: 20% functional cure (127 of 650) vs 0% placebo (0 of 328). B-Well 2: 19% functional cure (106 of 570) vs 0% placebo (0 of 286). In selected patients with low baseline HBsAg, the cure rate reached 26%. Grade 3 or higher adverse events occurred in 16% of bepirovirsen patients vs 3% placebo, with ALT elevations (6%) the most common.

The FDA granted Priority Review and Breakthrough Therapy designation. The bepirovirsen primer covers the regulatory risks in depth. The key concern, flagged by Anna Lok in the NEJM editorial, is durability. HBsAg loss must persist beyond the 72-week assessment, and patients with baseline HBsAg above 3,000 IU/mL or cirrhosis were excluded and need alternative therapies. The FDA may narrow the label to the low-HBsAg subgroup, which limits the addressable market but does not block approval. The 240 million chronic HBV patients worldwide mean even a narrowed label is a substantial commercial opportunity.

For GSK at $104 billion, bepirovirsen peak sales of $2 to $4 billion represent 1.5 to 3% of revenue. Material but not stock-moving at the mega-cap level. For Ionis at $8.85 billion, the royalty stream and milestone payments are more meaningful, but Ionis’s thesis is platform-wide, not bepirovirsen-specific. The Ionis antisense platform analysis covers the broader antisense franchise.

Catalyst 3: INO-3107 (Oct 30) - The Micro-Cap Binary

Inovio (INO) at $0.677, $55.7 million market cap. This is the smallest company on the October slate by three orders of magnitude.

INO-3107 is a DNA immunotherapy targeting HPV-6 and HPV-11, the viral types that cause recurrent respiratory papillomatosis (RRP), a rare disease where benign papillomas grow recurrently in the airway and require repeated surgical excision. The Phase 1/2 trial (published in Nature Communications) enrolled 32 patients with a median of 4 surgeries per year. Results: 81.3% of patients had a reduction in surgical interventions, 28% achieved complete response (zero surgeries in the follow-up year), and 72% achieved 50% or greater surgery reduction. In a retrospective follow-up, the complete response rate rose to 50% at Year 2 and 54% at Year 3.

The BLA is under review via the accelerated approval pathway, with no AdCom planned. The single-arm trial design is the central risk. The FDA has approved drugs on single-arm data in rare diseases with no approved therapies, but RRP has no FDA-approved pharmacologic treatment, which strengthens the case. The counterargument is that the trial had no placebo control, and the primary endpoint (surgery reduction) is subjective and depends on surgeon behavior. The INO-3107 RRP PDUFA primer covers this tension.

At $55.7 million market cap, the binary is extreme. If INO-3107 is approved, Inovio has a rare disease drug with orphan exclusivity in a market with zero competitors. Peak sales of $200 to $400 million would re-rate the stock 5 to 10x. If the FDA issues a complete response letter requesting randomized data, the stock loses 50 to 80% and the company faces a cash crunch. This is a coin flip at a micro-cap, and the position-sizing rules from the phase 3 readouts framework apply: 0.5 to 1% of a biotech portfolio, maximum.

Risks Across the Slate

Both remaining catalysts carry FDA risk. Bepirovirsen is the first functional cure in HBV but faces label-narrowing risk on the durability question. INO-3107 has the most binary setup but the weakest data package (single-arm, subjective endpoint, micro-cap with limited cash). I-DXd is off the slate after the September 25 BLA withdrawal.

The best biotech stocks 2026 ranking placed I-DXd and bepirovirsen as top-tier catalysts for the year. October is when bepirovirsen and INO-3107 resolve; I-DXd was withdrawn before it reached the FDA.

Verdict: Ranked by Tradeable Risk-Reward

1. INO-3107 (INO) - Highest risk, highest reward. A $55.7 million company with a binary FDA decision and 5 to 10x upside on approval. The single-arm data and accelerated approval pathway make this a genuine coin flip. Position size at 0.5 to 1% of portfolio. This is the only catalyst where the stock actually moves on the decision.

2. Bepirovirsen (GSK/IONS) - The only approval this quarter that changes how a disease gets treated. The 20% vs 0% functional cure data is the first drug to clear HBV without indefinite therapy. But GSK at $104 billion will not move, and IONS at $8.85 billion is platform-valued. The tradeable thesis is Ionis as a platform play where bepirovirsen approval adds validation. Buy IONS ahead of the PDUFA for the platform story, not the single drug.

3. I-DXd (MRK) — withdrawn. Merck and Daiichi Sankyo pulled the SCLC BLA on September 25 after the FDA said the Phase 2 data don’t support accelerated approval. There is no October 10 decision to trade. The B7-H3 ADC thesis now rests on the Phase 3 IDeate-Lung02 readout and GSK’s Ris-Rez, not a near-term PDUFA.

Looking ahead to November: SVRA MOLBREEVI (Nov 22), BBIO Attruby sBLA (Nov 22), COGT bezuclastinib (Nov 30). The catalyst calendar does not slow down.